This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (21) Citing Articles via Google Scholar Google Scholar Articles by van der Steeg, W. A. Articles by Kastelein, J. J.P. Search for Related Content PubMed Articles by van der Steeg, W. A. Articles by Kastelein, J. J.P. Related Collections Related Articles

CLINICAL RESEARCH: CORONARY ARTERY DISEASE

High-Density Lipoprotein Cholesterol, High-Density Lipoprotein Particle Size, and Apolipoprotein A-I: Significance for Cardiovascular Risk

The IDEAL and EPIC-Norfolk Studies

Wim A. van der Steeg, MD^_*, Ingar Holme, PhD, S. Matthijs Boekholdt, MD, PhD^_*, Mogens Lytken Larsen, MD, DMSc, Christina Lindahl, MD, Erik S.G. Stroes, MD, PhD^_*, Matti J. Tikkanen, MD, PhD^||, Nicholas J. Wareham, MBBS, PhD^¶, Ole Faergeman, MD, DMSc, Anders G. Olsson, MD, PhD^#, Terje R. Pedersen, MD, PhD, Kay-Tee Khaw, MBBChir^_** and John J.P. Kastelein, MD, PhD^_*,_*

^_* Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
Center for Preventive Medicine, Ullevål University Hospital, Oslo, Norway
Department of Medicine-Cardiology A, Århus, Denmark
Pfizer Sweden, Täby, Sweden
^|| Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland
^¶ Medical Research Council Epidemiology Unit, Cambridge, United Kingdom
^# Department of Internal Medicine, University Hospital, Linköping, Sweden
^_** Department of Public Health and Primary Care, Institute of Public Health, University of Cambridge, Cambridge, United Kingdom.

Manuscript received July 30, 2007; revised manuscript received September 13, 2007, accepted September 24, 2007.

^_* Reprint requests and correspondence: Dr. John J. P. Kastelein, Academic Medical Center, Department of Vascular Medicine, Room F4-159.2, P. O. Box 22660, 1100 DD, Amsterdam, the Netherlands. (Email: j.j.kastelein{at}amc.uva.nl).

Objectives: This study was designed to assess the relationship of high-density-lipoprotein cholesterol (HDL-C), HDL particle size, and apolipoprotein A-I (apoA-I) with the occurrence of coronary artery disease (CAD), with a focus on the effect of very high values of these parameters.

Background: High plasma levels of HDL-C and apoA-I are inversely related to the risk of CAD. However, recent data suggest that this relationship does not hold true for very high HDL-C levels, particularly when a preponderance of large HDL particles is observed.

Methods: We conducted a post-hoc analysis of 2 prospective studies: the IDEAL (Incremental Decrease in End Points through Aggressive Lipid Lowering; n = 8,888) trial comparing the efficacy of high-dose to usual-dose statin treatment for the secondary prevention of cardiovascular events, and the EPIC (European Prospective Investigation into Cancer and Nutrition)-Norfolk case-control study, including apparently healthy individuals who did (cases, n = 858) or did not (control patients, n = 1,491) develop CAD during follow-up. In IDEAL, only HDL-C and apoA-I were available; in EPIC-Norfolk, nuclear magnetic resonance spectroscopy-determined HDL particle sizes were also available.

Results: In the IDEAL study, higher HDL-C proved a significant major cardiac event risk factor following adjustment for age, gender, smoking, apoA-I, and apoB. A similar association was observed for HDL particle size in EPIC-Norfolk. Increased risk estimates were particularly present in the high ends of the distributions. In contrast, apoA-I remained negatively associated across the major part of its distribution in both studies.

Conclusions: When apoA-I and apoB are kept constant, HDL-C and HDL particle size may confer risk at very high values. This does not hold true for very high levels of apoA-I at fixed levels of HDL-C and apoB. These findings may have important consequences for assessment and treatment of CAD risk.

Abbreviations and Acronyms   ApoA-I = apolipoprotein A-I   ApoB = apolipoprotein B   CAD = coronary artery disease   CETP = cholesteryl ester transfer protein   HDL-C = high-density lipoprotein cholesterol   LDL-C = low-density lipoprotein cholesterol   MCE = major coronary event   MI = myocardial infarction   NMR = nuclear magnetic resonance   OR = odds ratio   RR = relative risk

Related Articles

The Yin and Yang of High-Density Lipoprotein Cholesterol

Jacques Genest
J. Am. Coll. Cardiol. 2008 51: 643-644. [Full Text] [PDF]

This article has been cited by other articles:

				M. Srinivasan, B. A. Irving, K. Dhatariya, K. A. Klaus, S. J. Hartman, J. P. McConnell, and K. S. Nair Effect of Dehydroepiandrosterone Replacement on Lipoprotein Profile in Hypoadrenal Women J. Clin. Endocrinol. Metab., March 1, 2009; 94(3): 761 - 764. [Abstract] [Full Text] [PDF]

				A. N. DeMaria, O. Ben-Yehuda, J. J. Bax, G. K. Feld, B. H. Greenberg, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, S. M. Narayan, D. J. Sahn, et al. Highlights of the Year in JACC 2008. J. Am. Coll. Cardiol., January 27, 2009; 53(4): 373 - 398. [Full Text] [PDF]

				K. El Harchaoui, B. J. Arsenault, R. Franssen, J.-P. Despres, G. K. Hovingh, E. S.G. Stroes, J. D. Otvos, N. J. Wareham, J. J.P. Kastelein, K.-T. Khaw, et al. High-Density Lipoprotein Particle Size and Concentration and Coronary Risk Ann Intern Med, January 20, 2009; 150(2): 84 - 93. [Abstract] [Full Text] [PDF]

				R. Movva and D. J. Rader Laboratory Assessment of HDL Heterogeneity and Function Clin. Chem., May 1, 2008; 54(5): 788 - 800. [Abstract] [Full Text] [PDF]

				J. Genest The Yin and Yang of high-density lipoprotein cholesterol. J. Am. Coll. Cardiol., February 12, 2008; 51(6): 643 - 644. [Full Text] [PDF]